Trametinib clinical trials
Also written GSK1120212 and JTP-74057.
Includes 7 studies of Trametinib dimethyl sulfoxide.
How each study uses trametinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the trametinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 29 May 2013 · MEKINIST · NDA 204114 (FDA, Drugs@FDA; as trametinib dimethyl sulfoxide)
- European Union
- 30 Jun 2014 · Mekinist · EMEA/H/C/002643 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
165 studies that test it; most in 2018 (20); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 8 |
| 2011 | 7 |
| 2012 | 8 |
| 2013 | 12 |
| 2014 | 18 |
| 2015 | 10 |
| 2016 | 9 |
| 2017 | 16 |
| 2018 | 20 |
| 2019 | 6 |
| 2020 | 11 |
| 2021 | 11 |
| 2022 | 3 |
| 2023 | 5 |
| 2024 | 8 |
| 2025 | 7 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 52 · Other 114
GlaxoSmithKline (26) · Novartis Pharmaceuticals (20) · National Cancer Institute (NCI) (17) · M.D. Anderson Cancer Center (8) · Memorial Sloan Kettering Cancer Center (5) · University of California, San Francisco (5) · Melanoma Institute Australia (3) · The Netherlands Cancer Institute (3)
Often tested with
Tested in the same studies.
Dabrafenib (58) · Nivolumab (8) · Pembrolizumab (8) · Palbociclib (6) · Hydroxychloroquine (5) · Binimetinib (4) · Pertuzumab (4) · Trastuzumab (4)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 1 phase 3 study under way
Trametinib is the comparator. A study of two new drugs counts under both.
- 1Cabozantinib · ECOG-ACRIN Cancer Research Group · next primary completion Sep 2030
Reaching primary completion within a year · 12
Studies that test trametinib.
- Nov 2026Pediatric Long-Term Follow-up and Rollover StudyPhase 4 · Novartis Pharmaceuticals
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
- Dec 2026Clinical Study of Neoadjuvant Targeted Therapy for AmeloblastomaPhase 2 · Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Feb 2027Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaPhase 2 · Novartis Pharmaceuticals
- Mar 2027Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.Phase 2 · St. Justine's Hospital
- Apr 2027Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 MutationPhase 2 · M.D. Anderson Cancer Center
- Jun 2027Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid CancerPhase 2 · Memorial Sloan Kettering Cancer Center
- Jun 2027Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile PatientsPhase 2 · Anna Raciborska
- Jul 2027Trametinib Treatment for Complicated Vascular AnomaliesPhase 1/2 · West China Hospital
- Sep 2027Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid CancerEarly Phase 1 · Memorial Sloan Kettering Cancer Center
Studies
Open first, then newest update. How each study uses trametinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 166
- Dabrafenib and/or Trametinib Rollover StudyRecruitingPhase 4Novartis PharmaceuticalsNCT03340506Written as trametinibHow we know
- The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer DrugsRecruitingPhase 2Helsinki University Central HospitalNCT05159245Written as TrametinibHow we know
- Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade GliomasRecruitingPhase 2University of California, San FranciscoNCT07110246Written as TrametinibHow we know
- 24VA021; VATCH Trametinib for Ras/MAPK Pathway VAsRecruitingPhase 2Children's Hospital of PhiladelphiaNCT07549646Written as TrametinibHow we know
- Clinical Trial of a MEK Inhibitor for RASopathy-Associated Severe Infantile Hypertrophic Cardiomyopathy: Baby MERITNot yet recruitingPhase 3Carelon ResearchNCT07817186Written as TrametinibHow we know
- A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaRecruitingPhase 1/2Therapeutic Advances in Childhood Leukemia ConsortiumNCT05849662Written as TrametinibHow we know
- Pediatric Low Grade Glioma - MEKinhibitor TRIal vs ChemotherapyRecruitingPhase 2University Hospital, Strasbourg, FranceNCT05180825Written as TrametinibHow we know
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingPhase 1University of California, San FranciscoNCT04485559Written as TrametinibHow we know
- DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.RecruitingPhase 2/3Cancer Research UKNCT07440290Written as TrametinibHow we know
- MRD-positive AML Clinical StudyRecruitingNot applicableInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07131059Written as TrametinibHow we know
- MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric GliomasRecruitingPhase 1/2Ann & Robert H Lurie Children's Hospital of ChicagoNCT06712875Written as Trametinib and NivolumabHow we know
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingPhase 2Centre Leon BerardNCT04116541Written as TrametinibHow we know
- DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening ProtocolRecruitingPhase 2/3Cancer Research UKNCT05722886Written as Dabrafenib in combination with trametinibHow we know
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Dabrafenib+TrametinibHow we know
- Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, TrametinibRecruitingPhase 2Cook Children's Health Care SystemNCT06582745Written as TrametinibHow we know
- A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With OsteosarcomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07477457Written as TrametinibHow we know
- HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological MalignanciesRecruitingPhase 1/2Princess Maxima Center for Pediatric OncologyNCT05658640Written as TrametinibHow we know
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingPhase 4Fujian Medical UniversityNCT07010393Written as TrametinibHow we know
- Imatinib and Trametinib for KRAS-mutated Solid TumorRecruitingPhase 1China Medical University HospitalNCT06962254Written as TrametinibHow we know
- Precision Cancer Therapy in Rare CancersRecruitingPhase 2Oslo University HospitalNCT06119789Written as TrametinibHow we know
See all 166 studies that test trametinib →
Given beside what is tested · 71 — trametinib is usual care or a partner of the new treatment
- Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive MalignanciesRecruitingPhase 1/2Institut de Recherches Internationales ServierNCT05786924Written as TrametinibHow we know
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Written as TrametinibHow we know
- Pulsed Stereotactic Ablative Radiotherapy (PULSAR) With Systematic Therapy for Thyroid CancerNot yet recruitingPhase 2Washington University School of MedicineNCT07886905Written as TrametinibHow we know
- Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated CholangiocarcinomaRecruitingPhase 1/2GenfitNCT05874414Written as GNS561 + TrametinibHow we know
- A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid TumorsRecruitingPhase 1Vividion Therapeutics, Inc.NCT06804824Written as TrametinibHow we know
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as TrametinibHow we know
- A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 1/2Bristol-Myers SquibbNCT05372354Written as TrametinibHow we know
- XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 MutationNot yet recruitingPhase 1/2Xynomic Pharmaceuticals, Inc.NCT05275374Written as TrametinibHow we know
- A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)RecruitingPhase 2Olivia Newton-John Cancer Research InstituteNCT05182931Written as Trametinib 2 MGHow we know
- Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid TumorsActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT02079740Written as TrametinibHow we know
- Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT04439292Written as Trametinib Dimethyl SulfoxideHow we know
- Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has SpreadActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02196181Written as Trametinib Dimethyl SulfoxideHow we know
- Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 MelanomaActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02224781Written as Trametinib Dimethyl SulfoxideHow we know
- Trametinib With or Without Whole Brain Radiation Therapy in Treating Patients With Brain MetastasesActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02015117Written as TrametinibHow we know
- Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade GliomaActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03919071Written as Trametinib Dimethyl SulfoxideHow we know
- Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingPhase 1Novartis PharmaceuticalsNCT03333343Written as trametinibHow we know
- Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study TreatmentsActive, not recruitingPhase 1/2Novartis PharmaceuticalsNCT07468071Written as trametinibHow we know
- Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedPhase 1/2Novartis PharmaceuticalsNCT05358249Written as trametinibHow we know
- Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K MelanomaTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04527549Written as Trametinib dimethyl sulfoxideHow we know
- A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)Active, not recruitingPhase 1Boehringer IngelheimNCT04111458Written as TrametinibHow we know
Showing 20 of 71.
As the comparator · 1 — what is tested is compared with trametinib
Codes
What other systems call trametinib · ClinicalTrials.gg INT005875
- MeSH (NLM) C560077trametinibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 33E86K87QNTRAMETINIBConfirmed FDA, NLM, Wikidata
- RxNorm 1425099Confirmed FDA, Wikidata
- Wikidata Q7833138trametinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C77908TrametinibOne source FDA
- DrugBank DB08911One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C560077 | trametinib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 33E86K87QN | TRAMETINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1425099 | — | Confirmed FDA, Wikidata |
| Wikidata | Q7833138 | trametinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C77908 | Trametinib | One source FDA |
| DrugBank | DB08911 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.